Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N5YA
|
|||
| Former ID |
DAP000133
|
|||
| Drug Name |
Repaglinide
|
|||
| Synonyms |
Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Approved | [1], [2] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Company |
Novo Nordisk
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H36N2O4
|
|||
| Canonical SMILES |
CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
|
|||
| InChI |
1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
|
|||
| InChIKey |
FAEKWTJYAYMJKF-QHCPKHFHSA-N
|
|||
| CAS Number |
CAS 135062-02-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9872, 7847660, 7980507, 8190080, 11112894, 11467074, 11468194, 11486642, 12014667, 14808699, 14833410, 24724596, 26719812, 43122707, 46386564, 46508150, 47425572, 48244693, 48319772, 48395177, 48416511, 49648522, 49699266, 49888451, 50100536, 52108264, 53789672, 57315871, 81092844, 85788088, 92125938, 92308165, 92308498, 92719265, 93166496, 99218180, 99431925, 99437146, 103394824, 103914669, 104041348, 104179029, 104335174, 117545849, 117873275, 121363609, 124659000, 124757239, 124799919, 125164043
|
|||
| ChEBI ID |
CHEBI:8805
|
|||
| ADReCS Drug ID | BADD_D01924 | |||
| SuperDrug ATC ID |
A10BX02
|
|||
| SuperDrug CAS ID |
cas=135062021
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.384; p = 0.007). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.517; p = 0.04). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.508; p = 0.004). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.508; p = 0.004). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.357; p = 0.041). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.435; p = 0.003). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.748; p = 0.024). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.325; p = 0.036). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.504; p = 0.045). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Repaglinide can be metabolized by Odoribacter splanchnicus (log2FC = -0.38; p = 0.023). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATP-binding cassette transporter C8 (ABCC8) | Target Info | Blocker | [4], [5], [6] |
| ATP-binding cassette transporter C9 (ABCC9) | Target Info | Blocker | [4], [5], [6] | |
| KEGG Pathway | ABC transporters | |||
| Insulin secretion | ||||
| Type II diabetes mellitus | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pancreas Function | ||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| Reactome | ABC-family proteins mediated transport | |||
| Regulation of insulin secretion | ||||
| WikiPathways | Potassium Channels | |||
| Integration of energy metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6841). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077571. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. | |||
| REF 5 | Pharmacological modulation of K(ATP) channels. Biochem Soc Trans. 2002 Apr;30(2):333-9. | |||
| REF 6 | Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41(7):471-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.